Results 11 to 20 of about 51,116 (225)

Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF

European Heart Journal, 2023
Aims The PARAGLIDE-HF trial demonstrated reductions in natriuretic peptides with sacubitril/valsartan compared with valsartan in patients with heart failure (HF) with mildly reduced or preserved ejection fraction who had a recent worsening HF event, but ...
M. Vaduganathan, R. Mentz, B. Claggett, Z. Miao, I. Kulac, Jonathan H. Ward, A. Hernandez, D. Morrow, R. Starling, E. Velazquez, K. Williamson, Akshay S. Desai, S. Zieroth, M. Lefkowitz, J. McMurray, E. Braunwald, S. Solomon   +16 more
semanticscholar   +1 more source

Tacrolimus Induced Hypertension and Vascular Remodeling Includes Mechanisms of Cellular Senescence-The Protective Effect of Valsartan. [PDF]

Acta Physiol (Oxf)
ABSTRACT Aim Calcineurin inhibitors (CNI) such as tacrolimus (Tac) are the first‐line treatment to prevent transplant rejection. However, CNI have adverse effects on blood vessels and renal function, which may be linked to cellular senescence. Valsartan, a common angiotensin II type 1 receptor (AT1R) blocker, exhibits anti‐senescence properties.
Fei L, Wang X, Kong L, Cui T, Khedkar PH, Xiang Y, Zhao D, Fang J, Liang Y, Zhang Y, Xu N, Qiu X, Zhao L, Zhang G, Lei Y, Tang C, Ma K, Lu L, Wei J, Lai EY, Persson PB, Patzak A, Zheng Z, Jiang S.   +23 more
europepmc   +2 more sources

Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre–Heart Failure With Preserved Ejection Fraction

JAMA cardiology, 2023
Key Points Question Can neprilysin inhibition improve markers of cardiovascular structure and function in patients with pre–heart failure with preserved ejection fraction?
M. Ledwidge, J. Dodd, F. Ryan, C. Sweeney, K. McDonald, Rebecca S Fox, Elizabeth Shorten, Shuaiwei Zhou, C. Watson, J. Gallagher, N. McVeigh, D. Murphy, K. McDonald   +12 more
semanticscholar   +1 more source

Updated insights on dementia‐related risk of sacubitril/valsartan: A real‐world pharmacovigilance analysis

CNS Neuroscience & Therapeutics, 2023
Aim Sacubitril/valsartan is a new cardiovascular agent characterized by its dual inhibition on the reninangiotensin system (RAS) and the neprilysin. As neprilysin also involved itself in the degradation of amyloid‐β, there is an ongoing concern about the
Congqin Chen, Lingqing Ding, Fang Fu, Jie Xiao   +3 more
semanticscholar   +1 more source

Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

JAMA cardiology, 2021
Importance The use of sacubitril/valsartan is not endorsed by practice guidelines for use in patients with New York Heart Association class IV heart failure with a reduced ejection fraction because of limited clinical experience in this population ...
D. Mann, M. Givertz, J. Vader, R. Starling, P. Shah, S. McNulty, K. Anstrom, K. Margulies, M. Kiernan, C. Mahr, D. Gupta, M. Redfield, A. Lala, G. Lewis, A. DeVore, P. Desvigne‐Nickens, Adrian F. Hernandez, E. Braunwald   +17 more
semanticscholar   +1 more source

Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients with Heart Failure.

Journal of the American College of Cardiology, 2023
BACKGROUND Some patients with heart failure may experience transient changes in kidney function upon transition to sacubitril/valsartan. Whether such changes portend adverse outcomes or influence long-term treatment benefits with sacubitril/valsartan ...
S. Chatur, B. Claggett, Finnian R. McCausland, J. Rouleau, M. Zile, M. Packer, M. Pfeffer, M. Lefkowitz, J. McMurray, S. Solomon, M. Vaduganathan   +10 more
semanticscholar   +1 more source

Sacubitril/Valsartan and Cognitive Outcomes in Heart Failure With Reduced Ejection Fraction

JACC: Advances, 2023
Background Recent trial data refute concerns about neurocognitive off-target effects of neprilysin inhibition with sacubitril and suggest benefit in patients with heart failure and ejection fraction >40%.
P. Grewal, Alan Abboud, E. P. Myserlis, M. Goldschmidt, J. Butler, H. Skopicki, A. Kalogeropoulos   +6 more
semanticscholar   +1 more source

Valsartan, Losartan and Irbesartan use in the USA, UK, Canada and Denmark after the nitrosamine recalls: a descriptive cohort study

BMJ Open, 2023
Objectives To examine valsartan, losartan and irbesartan usage and switching patterns in the USA, UK, Canada and Denmark before and after July 2018, when the first Angiotensin-Receptor-Blocker (ARB) (valsartan) was recalled.
E. Eworuke, Mayura U. Shinde, Laura Hou, M. Paterson, P. B. Jensen, Judith C. Maro, Ashish Rai, Daniel Scarnecchia, Dinci D. Pennap, D. Woronow, R. Ghosh, Stephen J. Welburn, A. Pottegård, Robert W. Platt, Hana Lee, M. Bradley   +15 more
semanticscholar   +1 more source

The history and mystery of sacubitril/valsartan: From clinical trial to the real world

Frontiers in Cardiovascular Medicine, 2023
Heart failure is a serious threat to human health, with morbidity and mortality rates increasing despite the existence of multiple treatment options. Therefore, it is necessary to identify new therapeutic targets for this disease. Sacubitril/valsartan is
Mingsong Zhang, Yifei Zou, Yang-xue Li, He-ling Wang, Wei Sun, B. Liu   +5 more
semanticscholar   +1 more source

A Retrospective Analysis of Human Angiotensin II Receptor Blockers (ARB) Pharmacokinetics, Dosages and C_max Values for the Experimental Modelling of Pleiotropic and Supratherapeutic Activities. [PDF]

Basic Clin Pharmacol Toxicol
ABSTRACT Angiotensin II (AngII) receptor blockers (ARBs) are medications that lower systolic blood pressure (BP) by antagonizing the AngII type 1 receptor (AT1). However, ARBs have documented or suspected therapeutic properties in diseases not caused by high BP including diabetes, muscular dystrophy, chronic obstructive pulmonary diseases (COPD) and ...
Evans A, Bernatchez P.
europepmc   +2 more sources